Please login to the form below

Not currently logged in
Email:
Password:

New sNDA for AZ's Symbicort

AstraZeneca has submitted a supplemental new drug application to the US Food and Drug Administration for its COPD product, Symbicort
AstraZeneca (AZ) has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for its COPD product, Symbicort.

Results from two pivotal efficacy and safety trials showed that Symbicort (budesonide/formoterol) could be a potential inhalation aerosol treatment for patients with chronic obstructive pulmonary disease (COPD). Patients with moderate-to-severe COPD were given Symbicort during the studies. According to AZ, the medication was well tolerated and efficacious.

Howard Hutchinson, chief medical officer at AZ, said: "We are confident in the data from Shine and Sun trials that support our submission and we look forward to discussions with the FDA about this potential expanded indication."

Symbicort is currently approved in the US for the treatment of asthma in patients over 12-years-old to help manage their condition. AZ said that the drug met pre-specified endpoints during clinical studies, prompting the firm to file the sNDA.

2nd May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics